Royal Bank of Canada Reaffirms “Outperform” Rating for Allogene Therapeutics (NASDAQ:ALLO)
Royal Bank of Canada reissued their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. A number of other research analysts have also recently weighed in on the stock. HC Wainwright lowered their […]
Royal Bank of Canada reissued their outperform rating on shares of Allogene Therapeutics (NASDAQ:ALLO – Free Report) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $10.00 price objective on the stock. A number of other research analysts have also recently weighed in on the stock. HC Wainwright lowered their […]
